COLL

Scott Dreyer

Known title: EVP & Chief Commercial OfficerCIK: 0001746251

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.

this person other insiders at COLL

Transaction History

COLL▼ Sell$1.9M
COLL▼ Sell$146K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▼ Sell$466K
COLL▼ Sell$1.0M
COLL▲ Buy$280K
COLL▼ Sell$533K
COLL▼ Sell$315K
COLL▲ Buy$350K
COLL▼ Sell$626K
COLL▲ Buy$104K
COLL▼ Sell$185K
COLL▼ Sell$567K
COLL▼ Sell$58K
COLL▼ Sell$68K
COLL▼ Sell$70K
COLL▼ Sell$462K
COLL▼ Sell$99K
COLL▼ Sell$243K
COLL▼ Sell$661K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▲ Buy$572K
COLL▼ Sell$1.9M
COLL▲ Buy$1.2M
COLL▼ Sell$1.7M
COLL▼ Sell$340K
COLL▼ Sell$25K
COLL▼ Sell$659K
COLL▼ Sell$342K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▼ Sell$761K
COLL▼ Sell$356K
COLL▼ Sell$389K
COLL▼ Sell$182K
COLL▲ Buy—
COLL▲ Buy$0
COLL▼ Sell$204K
COLL▼ Sell$2K
COLL▼ Sell$282K
COLL▼ Sell$10K
COLL▼ Sell$228K
COLL▼ Sell$117K
COLL▼ Sell$71K
COLL▲ Buy$0
COLL▲ Buy—
COLL▼ Sell$13K
COLL▼ Sell$104K

We use analytics to understand how market-wall is used. No personal data is sold.